BioCentury | Jul 28, 2020
Politics, Policy & Law

Biopharma industry accelerates attacks on Trump

Last week the White House invited Pfizer Chairman and CEO Albert Bourla to join a group of his peers at the White House Tuesday to discuss drug pricing with President Donald Trump. Instead of traveling...
BioCentury | Jul 27, 2020
Politics, Policy & Law

Biopharma boycotts White House meeting

Biopharmaceutical industry CEOs informed the White House Monday that they would not attend a meeting that had been scheduled for Tuesday with President Donald Trump. As a result of the CEO boycott, the White House...
BioCentury | Jul 1, 2020
Finance

Goldfinch’s $100M round sets up Third Rock company to advance kidney disease therapies

With $100 million in series B funding, Goldfinch Bio Inc. aims to move its second kidney disease therapy into the clinic and begin Phase II testing of its lead candidate. Eventide Asset Management led the...
BioCentury | May 21, 2020
Finance

With repurposed antiviral, Atea draws $215M as it preps Phase II COVID-19 trial

Led by veteran biotech entrepreneur Jean-Pierre Sommadossi, Atea believes an antiviral it had been developing to treat HCV has promise to treat COVID-19 in a population that extends beyond hospitalized patients. The company said Wednesday...
BioCentury | May 20, 2020
Finance

Quality control company Rapid Micro raises $120M in equity and debt

Rapid Micro hopes to use its new $120 million debt and equity infusion for commercial expansion of its automated contaminant testing product for drug manufacturers, as well as a new rapid sterility test backed by...
BioCentury | Feb 12, 2020
Product Development

Freeline seeking ‘normal’ Factor IX activity via hemophilia gene therapy

Freeline has posted clinical potency data for its hemophilia B gene therapy that suggest its treatment could outperform its more advanced competitors. Chris Hollowood, Freeline Therapeutics Ltd. executive chairman and Syncona Ltd. chief investment officer,...
BioCentury | Feb 4, 2020
Deals

First newco from BMS-BioMotiv deal launches to target fibrosis, inflammation

Five months after forming a build-to-buy partnership, BMS and pharmaceutical accelerator BioMotiv have launched their first company. Anteros Pharmaceuticals will develop small molecules to treat fibrotic and inflammatory diseases. As part of the partners' September...
BioCentury | Jan 18, 2020
Politics, Policy & Law

Final reg reduces numbers of biopharma companies subject to CFIUS reviews

Final regulations implementing the Foreign Investment Risk Review Modernization Act of 2018 released on Jan. 14 represent a partial victory for the biopharma industry, but the process is still certain to cast a cloud over...
BioCentury | Nov 5, 2019
Financial News

Following JV, Sino backs Akeso's $150M series D

Six months after establishing a joint venture with Akeso, Sino Biopharmaceutical has co-led a series D round of about $150 million in the Zhongshan-based cancer and autoimmune company. Loyal Valley Capital co-led the round, which...
BioCentury | Nov 1, 2019
Politics & Policy

Trump administration shifts Sharpless to make way for Hahn

The Trump administration has launched a game of musical chairs that is intended to clear a path for Stephen Hahn to be confirmed as FDA commissioner. When the music stops, it is possible that Hahn...
Items per page:
1 - 10 of 374